Marker for determining sensitivity triple combination anti-cancer agent

Providing marker for determining sensitivity to an anticancer agent and a new cancer treatment means make use of it can determine the therapeutic response of the individual patient. ALAD gene, C20orf43 gene, Cables1 gene, CDC14B genes, GDA gene, HOXB6 gene, RPL7AP27 gene, consisting of one or more genes selected from the TMEM18 gene and UGT2B10 gene, oxaliplatin or a salt thereof and fluorouracil or a salt thereof and Rebohorinato or marker for determining sensitivity of anticancer agents including salts.